Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Report is Segmented by Cancer Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors and Other Cancer Types), Modality (Diagnosis and Therapeutics), and Geography (GCC, South Africa and Rest of Middle East and Africa). The Report Offers the Value (in USD) for the Above Segments.

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

MEA Ovarian Cancer Diagnostics & Therapeutics Market Size

View Global Report
Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 263.92 Million
Market Size (2030) USD 386.00 Million
CAGR (2025 - 2030) 7.90 %
Market Concentration Low

Major Players

Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

MEA Ovarian Cancer Diagnostics & Therapeutics Market Analysis

The Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size is estimated at USD 263.92 million in 2025, and is expected to reach USD 386.00 million by 2030, at a CAGR of 7.9% during the forecast period (2025-2030).

The COVID-19 pandemic impacted the growth of the Middle East and African cancer diagnostics and therapeutics market. For instance, an article published by the National Centre for Biotechnology Information (NCBI) in May 2022 reported that the COVID-19 pandemic has disrupted cancer care to a certain degree in Saudi Arabia. The article also reported that women with ovarian cancer had disruptions in their treatment plans during COVID-19 due unavailability of proper ovarian cancer diagnostics in the country, as a result of the growth of the studied market being hampered due to COVID-19. In the current scenario, it is expected that with the decrease in COVID-19 cases and ease in restriction, diagnostics services may resume in the country. Thus, the studied market is expected to witness growth over the forecast period.

The major factors that are responsible for the growth of the market include the growing burden of ovarian cancer and the use of combination therapies for the treatment of ovarian cancer. An article published by the American Society of Clinical Oncology Journal in March 2022 reported that, of 463,675 new cancer cases estimated to be in Arab countries, 5.2% of the total cancers accounted for ovarian cancers. Similarly, another article published by NCBI in April 2022 reported that the prevalence of ovarian cancer in South Africa was 4.9% in the year 2020-2021. Thus, the high prevalence of ovarian cancer is increasing the demand for ovarian cancer diagnostics and therapeutics in the MENA region, thereby driving the growth of the studied market.

Also, another article published by the Saudi Pharmaceutical Journal in January 2023 reported that in Saudi Arabia, according to the National Cancer Registry, ovarian cancer is the seventh most common cancer, representing 3.3 % of the total cancers affecting women. The article also quoted that ovarian cancer is the 10th most lethal cancer among several other cancers as per the latest data from the International Agency for Research on Cancer. Thus, such instances are driving the demand for diagnostics and therapeutics for the studied market.

Furthermore, technological developments and new product launches are expected to drive the growth of the studied market. For instance, in February 2023, United Imaging, a global innovator in cutting-edge medical imaging and radiotherapy equipment, attended Arab Health 2023 as a Platinum partner in Dubai, UAE, with a broad range of state-of-the-art medical imaging devices, including HD TOF PET/MR uPMR 790; cardiac CT, the ultra-fast high-resolution digital PET/CT uMI 780; the newly launched uAiFI-powered 1.5T Wide Bore MRI System with "3T-like" performance, the uMR 680; and the most compact mobile DR system, uDR 380i Pro. Thus,

Thus, the growing burden of ovarian cancer and the new product launches are driving the growth of the studied market. However, a lack of awareness in emerging and low-income economies is slowing down the growth of the studied market.

MEA Ovarian Cancer Diagnostics & Therapeutics Industry Overview

The Middle East and African ovarian cancer diagnostics and therapeutics market is moderately competitive and comprised of a few companies operating locally and regionally. With the rising research and development, the companies working in this market segment are launching novel products, and more companies are expected to penetrate the market. Some of the companies operating in this market segment are AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline Plc, Johnson and Johnson (Janssen Pharmaceuticals), Pfizer Inc. and Siemens Healthineers AG.

MEA Ovarian Cancer Diagnostics & Therapeutics Market Leaders

  1. Astrazeneca plc

  2. Bristol Myers Squibb Company

  3. F. Hoffman-La Roche Ltd

  4. Johnson and Johnson (Janssen Pharmaceuticals)

  5. Siemens Healthineers AG

  6. *Disclaimer: Major Players sorted in no particular order
Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

MEA Ovarian Cancer Diagnostics & Therapeutics Market News

  • February 2023: San Francisco-based iSono Health partnered with Middle East-based Abdul Latif Jameel Health to become the exclusive distributor of iSono Health’s ATUSA scanner (AI-driven portable 3D breast ultrasound scanner) in UAE. This partnership is a significant milestone in making our ATUSA scanner accessible to millions more women across the UAE.
  • September 2022: Accuracy Incorporated reported that the company was expanding its global footprint with the introduction of its CyberKnife platform in Africa, making it possible for more patients to obtain access to the extremely precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments the system delivers.

MEA Ovarian Cancer Diagnostics & Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Ovarian Cancer
    • 4.2.2 Use of Combination Therapies for the Treatment of Ovarian Cancer
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness in Emerging and Low Income Economies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Value in USD)

  • 5.1 By Cancer Type
    • 5.1.1 Epithelial Ovarian Tumors
    • 5.1.2 Ovarian Germ Cell Tumors
    • 5.1.3 Other Cancer Types
  • 5.2 By Modality
    • 5.2.1 Diagnostics
    • 5.2.1.1 Biopsy
    • 5.2.1.2 Blood Tests
    • 5.2.1.3 Ultrasound
    • 5.2.1.4 PET
    • 5.2.1.5 CT Scan
    • 5.2.1.6 Other Diagnostics
    • 5.2.2 Therapeutics
    • 5.2.2.1 Chemotherapy
    • 5.2.2.2 Radiation Therapy
    • 5.2.2.3 Immunotherapy
    • 5.2.2.4 Hormonal Therapy
    • 5.2.2.5 Other Therapecutics
  • 5.3 Geography
    • 5.3.1 GCC
    • 5.3.2 South Africa
    • 5.3.3 Rest of Middle East and Africa

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Astrazeneca plc
    • 6.1.2 Bristol Myers Squibb Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffman-La Roche Ltd
    • 6.1.5 Glaxosmithkline Plc
    • 6.1.6 Johnson and Johnson (Janssen Pharmaceuticals)
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Siemens Healthineers AG
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

MEA Ovarian Cancer Diagnostics & Therapeutics Industry Segmentation

As per the scope of the report, ovarian cancer is a type of cancer that begins in the ovaries. There are several types of ovarian cancer. Epithelial ovarian cancer is the most common type of ovarian cancer. Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women. The Middle East and Africa ovarian cancer diagnostics and therapeutics market is segmented by cancer type (epithelial ovarian tumors, ovarian germ cell tumors, and other cancer types), modality (diagnosis (biopsy, blood tests, ultrasound, PET, CT scan, and other diagnostics), and therapeutics (chemotherapy, radiation therapy, immunotherapy, hormonal therapy, and other therapeutics), and geography (GCC, South Africa, and the Rest of the Middle East and Africa).

The report offers the value (in USD) for the above segments.

By Cancer Type Epithelial Ovarian Tumors
Ovarian Germ Cell Tumors
Other Cancer Types
By Modality Diagnostics Biopsy
Blood Tests
Ultrasound
PET
CT Scan
Other Diagnostics
By Modality Therapeutics Chemotherapy
Radiation Therapy
Immunotherapy
Hormonal Therapy
Other Therapecutics
Geography GCC
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

MEA Ovarian Cancer Diagnostics & Therapeutics Market Research FAQs

How big is the Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market?

The Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size is expected to reach USD 263.92 million in 2025 and grow at a CAGR of 7.90% to reach USD 386.00 million by 2030.

What is the current Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size?

In 2025, the Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size is expected to reach USD 263.92 million.

Who are the key players in Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market?

Astrazeneca plc, Bristol Myers Squibb Company, F. Hoffman-La Roche Ltd, Johnson and Johnson (Janssen Pharmaceuticals) and Siemens Healthineers AG are the major companies operating in the Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market.

What years does this Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market cover, and what was the market size in 2024?

In 2024, the Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size was estimated at USD 243.07 million. The report covers the Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

MEA Ovarian Cancer Diagnostics & Therapeutics Industry Report

Statistics for the 2025 Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Middle East & Africa Ovarian Cancer Diagnostics And Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.